FASENRA (benralizumab) - Granulomatosis with polyangiitis (EGPA) in adults

Opinions on drugs - Posted on Sep 15 2025

Reason for request

Modification of the listing conditions

Summary

Unfavourable opinion for reimbursement as an add-on treatment for adult patients withrelapsing or refractory eosinophilic granulomatosis with polyangiitis.

Clinical Benefit

Insufficient

The clinical benefit of FASENRA (benralizumab) is insufficient as an add-on treatment for adult patients with relapsing or
refractory eosinophilic granulomatosis with polyangiitis to justify public funding in view of the available alternative.